![]() Sylentis Sylentis is a biotechnology company focused on the development of ophthalmic drugs and therapies based on RNAi (gene silencing) technology. | ![]() Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. | ![]() AnGes AnGes is a biopharmaceutical company specializing in R&D and practical application of genetic medicine. | |
Founding Date | Founding Date 2006 | Founding Date 1995 | Founding Date 1999 |
Type | Type Private | Type Public | Type Public |
Tags | |||
Locations | Locations Tres Cantos, ES HQ Madrid, ES Mountain View, US | Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more | Locations Ibaraki, JP HQ Fujisawa, JP Ibaraki, JP Kawasaki, JP Minato City, JP Bethesda, US |
Employees | Employees 51 | Employees 20216% increase | Employees 5562% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 737.4 m | Valuation ($) 78.3 m |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $49.8m (FY, 2025) | Revenue (est.) ¥874.1m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $274k (FY, 2025) | Cost of goods ¥499.9m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $49.5m (FY, 2025) | Gross profit ¥374.2m (FY, 2025) |
Net income | Net income N/A | Net income ($50.3m) (FY, 2025) | Net income (¥5.1b) (FY, 2025) |

Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
View company
AnGes is a biopharmaceutical company specializing in R&D and practical application of genetic medicine.
View company